RL
73
5
FMC
23
7
MCO
67
3
AEE
51
3
KR
50
5
FSLR
50
6
TXT
46
4
PH
60
5
APA
30
5
CSCO
63
5
SNA
56
3
UAL
73
3
PM
49
8
NI
63
5
M
40
3
ORLY
48
3
IRM
33
5
PCG
59
9
SO
48
6
MSFT
55
2
RL
73
5
FMC
23
7
MCO
67
3
AEE
51
3
KR
50
5
FSLR
50
6
TXT
46
4
PH
60
5
APA
30
5
CSCO
63
5
SNA
56
3
UAL
73
3
PM
49
8
NI
63
5
M
40
3
ORLY
48
3
IRM
33
5
PCG
59
9
SO
48
6
MSFT
55
2
Financhill
Back

Apellis Pharmaceuticals 10K Form

Buy
53

APLS
Apellis Pharmaceuticals

Last Price:
$33.18
Seasonality Move:
14.66%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive APLS News And Ratings

See the #1 stock for the next 7 days that we like better than APLS

APLS Financial Statistics

Sales & Book Value

Annual Sales: $396.6M
Cash Flow: $34.1M
Price / Cash Flow: 0
Annual Sales: $1.94
Price / Book: 17.4

Profitability

EPS (TTM): -2.03000
Net Income (TTM): $-250.1M
Gross Margin: $338.1M
Return on Equity: -104.65%
Return on Assets: -29.46%

Apellis Pharmaceuticals Earnings Forecast

Key Apellis Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 6 years for APLS is 85.25%.
  • The Selling, General & Administrative Expenses for APLS have been equal to 126.28% of Gross Profit Margin.
  • The Research & Development expenses have been 89.36% of Revenue.
  • The Interest Expense is -5.60% of Operating Income.
  • The Net Earning history of APLS is -133.29% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Apellis Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: APLS
CUSIP: 03753U
Website: apellis.com

Debt

Debt-to-Equity Ratio: 1.91
Current Ratio: 4.36
Quick Ratio: 3.56

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

APLS Technical Analysis vs Fundamental Analysis

Buy
53
Apellis Pharmaceuticals (APLS) is a Buy

Is Apellis Pharmaceuticals a Buy or a Sell?